Related Experiment Video

Updated: Oct 7, 2025

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.6K

Design of a Potent TLX Agonist by Rational Fragment Fusion

Giuseppe Faudone1, Rezart Zhubi1,2, Fatih Celik1

  • 1Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, D-60438 Frankfurt, Germany.

Journal of Medicinal Chemistry
|January 6, 2022
PubMed

Insights

Researchers developed a potent TLX agonist, a crucial tool for studying neurodegenerative diseases. This new compound selectively targets tailless homologue (TLX) to advance potential treatments.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • The orphan nuclear receptor tailless homologue (TLX, NR2E1) is a master regulator of neurogenesis.
  • TLX maintains neuronal stem cell homeostasis by repressing tumor suppressor genes.
  • TLX is a potential therapeutic target for neurodegenerative diseases, but lacks potent modulators for research.

Purpose of the Study:

  • To develop a potent and selective TLX agonist as a tool for pharmacological studies.
  • To validate the potential of TLX as a therapeutic target for neurodegenerative diseases.

Main Methods:

  • Fragment screening and pharmacophore modeling were employed.
  • Fragment linkage and fusion strategies were utilized to design TLX modulators.
  • Compound 10 was identified as a potent TLX agonist.

Main Results:

  • A novel TLX agonist, compound 10, was successfully developed.
  • Compound 10 exhibits submicromolar potency and high selectivity for TLX.
  • The developed agonist is suitable for functional studies on TLX.

Conclusions:

  • The developed TLX agonist represents a valuable tool for investigating TLX function in neurogenesis and neurodegenerative diseases.
  • This research facilitates further validation of TLX as a therapeutic target.

More Related Videos

Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells14:02

Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells

Published on: April 9, 2018

8.6K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.2K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.0K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.4K
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.5K